Scarica l'app Stockscreener
0.00
100.00%
-0.36
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ATXI Giù?
Forum
Previsione
Frazionamento azionario
Avenue Therapeutics Inc Borsa (ATXI) Ultime notizie
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - The National Law Review
Postoperative Pain Management Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - Business Upturn
Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
State Street (NYSE: STT) discloses 5.5% beneficial stake in Lexeo Therapeutics (LXEO) - Stock Titan
Aprea Therapeutics, Inc. (APRE) stock price, news, quote and history - Yahoo Finance Singapore
State Street Corporation (ALLO) discloses 5.5% beneficial stake in Allogene - Stock Titan
Price to earnings forward of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView
Aldeyra Therapeutics (NASDAQ: ALDX) leases new Concord headquarters space - Stock Titan
Change Agents Corporation (CHGA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Avenue Therapeutics, Inc. Revenue Breakdown – OTC:ATXI - TradingView
Frontier tech research, news & data - MLQ.ai
Circio, Avenue Biosciences Partner on Gene Therapy Protein Expression - Contract Pharma
Cadrenal Therapeutics (CVKD) outlines $8.84M Rule 506(b) warrant financing - Stock Titan
Turn Therapeutics Inc.Common Stock (TTRX) Stock Price, News, Quote & History - FinancialContent
TG Therapeutics Initiates Phase 2 Trial of BRIUMVI in Treatment-Resistant Schizophrenia - Quiver Quantitative
Enterprise value to EBITDA forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to sales forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to book forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to sales forward of Avenue Therapeutics, Inc. – LSX:A40BWJ - TradingView
Enterprise value to EBIT forward of Avenue Therapeutics, Inc. – OTC:ATXI - TradingView
Price to earnings forward of Avenue Therapeutics, Inc. – LSX:A40BWJ - TradingView
Avenue Therapeutics, Inc. Actuals & Estimates (OTC:ATXI) - TradingView
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares - Business Wire
Avenue Therapeutics (ATXI) Q1 2026 earnings summary - Quartr
Avenue Therapeutics (ATXI) Q3 2024 earnings summary - Quartr
Avenue Therapeutics (ATXI) AGM 2024 Summary - Quartr
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering - Business Wire
Definium Therapeutics, Inc. Announces Proposed Public Offering - BioSpace
Fortress Biotech StockSaturday deep dive on the business model - AD HOC NEWS
Madison Avenue Partners LP Reduces Stock Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - StreetInsider
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds - StreetInsider
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - StreetInsider
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - TradingView
Antibody may improve treatment response in lung cancer: Newsroom - UT Southwestern
Summit Therapeutics Announces Proposed Public Offering of Common Stock - FinancialContent
Tango Therapeutics Announces Proposed $500 Million Public Offering - The Manila Times
Neuro stocks outpace broader markets as psychedelics, Axsome shine - BioWorld News
Chiesi (KALV) offers $27.00/share; HSR, German and Italian clearances noted - Stock Titan
Relay Therapeutics Announces Proposed Public Offering of Common Stock - Investing News Network
Madison Avenue entities (INDV) disclose 4.32M-share, ~3.5% stake - Stock Titan
Priority review voucher sale drives Fortress Biotech (FBIO) Q1 2026 profit and cash surge - Stock Titan
Jeremy Levin reports 4.5% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
Click Therapeutics Positions Over-the-Counter Digital Therapeutics as New Growth Avenue - TipRanks
State Street (VNDA) discloses 3.02M shares, 5.1% ownership on 13G - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) Rating Increased to Hold at Wall Street Zen - MarketBeat
MSN Money - MSN
Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know - MSN
AVENUE THERAPEUTICS, INC. 1Q 2026: Net loss $0.7M, Revenue $0— 10-Q Summary - TradingView
Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Avenue Therapeutics (OTC: ATXI) cuts Q1 loss but warns on going concern - Stock Titan
Avenue Therapeutics | 10-Q: Quarterly report - Moomoo
Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering - BioSpace
Board elections and auditor vote at MiNK Therapeutics (NASDAQ: INKT) - Stock Titan
Executive pay, major holders and votes in Foghorn (NASDAQ: FHTX) 2026 proxy - Stock Titan
Executive pay and audits headline Monte Rosa (NASDAQ: GLUE) 2026 proxy - Stock Titan
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering - The Manila Times
Akebia (NASDAQ: AKBA) plans major increase in authorized common shares - Stock Titan
Abeona Therapeutics (NASDAQ: ABEO) sets 2026 virtual meeting on directors, pay and equity plan - Stock Titan
Intellia Therapeutics Announces Proposed Public Offering of Common Stock - Intellia Therapeutics
Form S-1/A Hemab Therapeutics Holdi - StreetInsider
Spero Therapeutics (NASDAQ: SPRO) 2026 proxy adds stock increase and new incentive plan - Stock Titan
Catalyst Pharmaceuticals: Favorable Trial Outcome Could Be A Meaningful Overhang - Seeking Alpha
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
1.21%
1.07%
Capitalizzazione:
|
Volume (24 ore):